



Louisiana

Genetic Testing for Alzheimer's Disease

Policy # 00204

Original Effective Date: 05/17/2006

Current Effective Date: 11/21/2018

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

When Services May Be Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

Based on review of available data, the Company may consider targeted genetic testing for a known familial variant in the presenilin genes (PSEN) or amyloid-beta precursor protein (APP) gene associated with autosomal dominant early-onset Alzheimer disease (AD) in an asymptomatic individual to determine future risk of disease to be **eligible for coverage** when the following criteria are met:

Patient Selection Criteria

Coverage eligibility will be considered when all of the following criteria are met:

- The individual has a close relative (ie, first- or second-degree relative) with a known familial variant associated with autosomal dominant early-onset Alzheimer disease (AD) AND
- Results of testing will inform reproductive decision making.

Based on review of available data, the Company may consider genetic testing for variants in presenilin genes (PSEN) or amyloid-beta precursor protein (APP) gene associated with autosomal dominant early-onset Alzheimer disease (AD) in an asymptomatic individual to determine future risk of disease to be **eligible for coverage** when the following criteria are met:

Patient Selection Criteria

Coverage eligibility will be considered when all of the following criteria are met:

- The individual has a family history of dementia consistent with autosomal dominant Alzheimer disease (AD) for whom the genetic status of the affected family members is unavailable AND
- Results of testing will inform reproductive decision making.

When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Alzheimer's Disease

Policy # 00204

Original Effective Date: 05/17/2006

Current Effective Date: 11/21/2018

Based on review of available data, the Company considers genetic testing for the risk assessment of Alzheimer disease (AD) in asymptomatic individuals in all other situations to be **investigational**.^{*} Genetic testing includes, but is not limited to, testing for the apolipoprotein E ϵ 4 allele (*APOE*) or triggering receptor expressed on myeloid cells 2 (*TREM2*.)

Policy Guidelines

Genetic testing for AD may be offered along with analysis of CSF levels of the tau protein and amyloid- β peptide 1-42. This group of tests may be collectively referred to as the ADmark^{TM±} Profile, offered by Athena Diagnostics (Worcester, MA).

TESTING STRATEGY

The 2011 guidelines from the American College of Medical Genetics and Genomics (ACMG) and the National Society of Genetic Counselors recommended that genetic testing for early-onset, autosomal dominant AD should only occur in the context of genetic counseling with support by someone expert in the area. In asymptomatic patients, a testing protocol based on the 1994 International Huntington Association and World Federation of Neurology Research Group on Huntington's Chorea guidelines have been recommended. Consultation of the Alzheimer Disease & Frontotemporal Dementia Mutation Database has also recommended before disclosure of genetic test results.

A family history of autosomal dominant AD is suggested by 3 affected members in 2 generations. In individuals at risk of early-onset, autosomal dominant AD, ideally an affected family member should be tested first to identify the familial variant. If no affected family member is available for testing and an asymptomatic individual remains interested in testing to inform reproductive decision making, then in-depth sequencing of the 3 genes (*APP*, *PSEN1*, *PSEN2*) associated with autosomal dominant AD may be indicated.

GENETICS NOMENCLATURE UPDATE

The Human Genome Variation Society nomenclature is used to report information on variants found in DNA and serves as an international standard in DNA diagnostics. It is being implemented for genetic testing medical evidence review updates starting in 2017 (see Table PG1). The Society's nomenclature is recommended by the Human Variome Project, the HUMAN Genome Organization, and by the Human Genome Variation Society itself.

The American College of Medical Genetics and Genomics and the Association for Molecular Pathology standards and guidelines for interpretation of sequence variants represent expert opinion from both organizations, in addition to the College of American Pathologists. These recommendations primarily apply to genetic tests used in clinical laboratories, including genotyping, single genes, panels, exomes, and genomes. Table PG2 shows the recommended standard terminology—"pathogenic," "likely pathogenic,"

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Alzheimer’s Disease

Policy # 00204

Original Effective Date: 05/17/2006

Current Effective Date: 11/21/2018

“uncertain significance,” “likely benign,” and “benign”—to describe variants identified that cause Mendelian disorders.

Table PG1. Nomenclature to Report on Variants Found in DNA

Previous	Updated	Definition
Mutation	Disease-associated variant	Disease-associated change in the DNA sequence
	Variant	Change in the DNA sequence
	Familial variant	Disease-associated variant identified in a proband for use in subsequent targeted genetic testing in first-degree relatives

Table PG2. ACMG-AMP Standards and Guidelines for Variant Classification

Variant Classification	Definition
Pathogenic	Disease-causing change in the DNA sequence
Likely pathogenic	Likely disease-causing change in the DNA sequence
Variant of uncertain significance	Change in DNA sequence with uncertain effects on disease
Likely benign	Likely benign change in the DNA sequence
Benign	Benign change in the DNA sequence

ACMG: American College of Medical Genetics and Genomics; AMP: Association for Molecular Pathology.

GENETIC COUNSELING

Experts recommend formal genetic counseling for patients who are at risk for inherited disorders and who wish to undergo genetic testing. Interpreting the results of genetic tests and understanding risk factors can be difficult for some patients; genetic counseling helps individuals understand the impact of genetic testing, including the possible effects the test results could have on the individual or their family members. It should be noted that genetic counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing; further, genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

Background/Overview

ALZHEIMER DISEASE

AD is commonly associated with a family history; 40% of patients with AD have a least 1 other afflicted first-degree relative. Numerous genes have been associated with late-onset AD, while variants in chromosomes 1, 14, and 21 have been associated with early-onset familial AD.

Genetic Variants

Individuals with early-onset familial AD (ie, before age 65 years but as early as 30 years) form a small subset of AD patients. AD within families of these patients may show an autosomal dominant pattern of inheritance. Pathogenic variants in 3 genes have been identified in affected families: the APP gene,

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Alzheimer's Disease

Policy # 00204

Original Effective Date: 05/17/2006

Current Effective Date: 11/21/2018

presenilin 1 (PSEN1) gene, and presenilin 2 (PSEN2) gene. APP and PSEN1 variants have 100% penetrance absent death from other causes, while PSEN2 has 95% penetrance. A variety of variants within these genes has been associated with AD; variants in PSEN1 appear to be the most common. While only 3% to 5% of all patients with AD have early-onset disease, pathogenic variants have been identified in 70% or more of these patients. Identifiable genetic variants are, therefore, rare causes of AD.

Testing for the apolipoprotein $\epsilon 4$ allele (APOE*E4) among patients with late-onset AD and for APP, PSEN1, or PSEN2 pathogenic variants in the rare patient with early-onset AD have been investigated as an aid in diagnosis of patients presenting with symptoms suggestive of AD, or as a technique for risk assessment in asymptomatic patients with a family history of AD. Pathogenic in PSEN1 and PSEN2 are specific for AD; APP variants are also found in cerebral hemorrhagic amyloidosis of the Dutch type, a disease in which dementia and brain amyloid plaques are uncommon.

The APOE lipoprotein is a carrier of cholesterol produced in the liver and brain glial cells. The APOE gene has 3 alleles— $\epsilon 2$, 3, and 4—with the $\epsilon 3$ allele being the most common. Individuals carry 2 APOE alleles. The presence of at least one $\epsilon 4$ allele is associated with a 1.2- to 3-fold increased risk of AD, depending on the ethnic group. Among those homozygous for epsilon 4 ($\approx 2\%$ of the population), the risk of AD is higher than for those heterozygous for $\epsilon 4$. Mean age of onset of AD is about age 68 years for $\epsilon 4$ homozygotes, about 77 years for heterozygotes, and about 85 years for those with no $\epsilon 4$ alleles. About half of patients with sporadic AD carry an $\epsilon 4$ allele. However, not all patients with the allele develop AD. The $\epsilon 4$ allele represents a risk factor for AD rather than a disease-associated variant. In the absence of APOE testing, first-degree relatives of an individual with sporadic or familial AD are estimated to have a 2- to 4-fold greater risk of developing AD than the general population. There is evidence of possible interactions between $\epsilon 4$ alleles, other risk factors for AD (eg, risk factors for cerebrovascular disease such as smoking, hypertension, hypercholesterolemia, diabetes), and a higher risk of developing AD. However, it is not clear that all risk factors have been taken into account in such studies, including the presence of variants in other genes that may increase the risk of AD.

Studies have also identified rs75932628-T, a rare functional substitution for R47H on the triggering receptor expressed on myeloid cells 2 (*TREM2*), as a heterozygous risk variant for late-onset AD. On chromosome 6p21.1, at position 47 (R47H), the T allele of rs75932628 encodes a histidine substitute for arginine in the gene that encodes *TREM2*.

TREM2 is highly expressed in the brain and is known to have a role in regulating inflammation and phagocytosis. *TREM2* may serve a protective role in the brain by suppressing inflammation and clearing it of cell debris, amyloids, and toxic products. A decrease in the function of *TREM2* would allow inflammation in the brain to increase and may be a factor in the development of AD. The effect size of the *TREM2* variant confers a risk of AD that is similar to the APOE*E4 allele, although it occurs less frequently.

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Alzheimer's Disease

Policy # 00204

Original Effective Date: 05/17/2006

Current Effective Date: 11/21/2018

Diagnosis

The diagnosis of AD is divided into 3 categories: possible, probable, and definite AD. A diagnosis of definite AD requires postmortem confirmation of AD pathology, documenting the presence of extracellular β -amyloid plaques and intraneuronal neurofibrillary tangles in the cerebral cortex. As a result, a diagnosis of definite AD cannot be made during life, and the diagnosis of probable or possible AD is made on clinical grounds.⁷ Probable AD dementia is diagnosed clinically when the patient meets core clinical criteria for dementia and has a typical clinical course for AD. Criteria for diagnosis of probable AD have been developed by the National Institute on Aging and the Alzheimer's Association.⁶ These criteria require evidence of a specific pattern of cognitive impairment, a typical clinical course, and exclusion of other potential etiologies, as follows:

- Cognitive impairment
 - Cognitive impairment established by history from the patient and a knowledgeable informant, plus objective assessment by bedside mental status examination or neuropsychological testing
 - Cognitive impairment involving a minimum of two of the following domains:
 - Impaired ability to acquire and remember new information
 - Impaired reasoning and handling of complex tasks, poor judgment
 - Impaired visuospatial abilities
 - Impaired language functions
 - Changes in personality, behavior, or comportment
 - Initial and most prominent cognitive deficits are one of the following:
 - Amnesic presentation
 - Nonamnesic presentations, either a language presentation with prominent word-finding deficits; a visuospatial presentation with visual cognitive defects; or a dysexecutive presentation with prominent impairment of reasoning, judgment, and/or problem-solving.
- Clinical course
 - Insidious onset
 - Clear-cut history of worsening over time
 - Interference with the ability to function at work or usual activities
 - Decline from previous level of functioning and performing
- Exclusion of other disorders
 - Cognitive decline not explained by delirium or major psychiatric disorder
 - No evidence of other active neurologic disease, including substantial cerebrovascular disease or dementia with Lewy bodies.
 - Lack of prominent features of variant frontotemporal dementia or primary progressive aphasia.
 - No medication used with substantial effects on cognition.

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Alzheimer's Disease

Policy # 00204

Original Effective Date: 05/17/2006

Current Effective Date: 11/21/2018

A diagnosis of possible AD dementia is made when the patient meets most of the AD criteria but has an atypical course or an etiologically mixed presentation. This may consist of an atypical onset (eg, sudden onset) or atypical progression. A diagnosis of possible AD is also made when there is another potentially causative systemic or neurologic disorder that is not thought to be the primary etiology of dementia.

Mild cognitive impairment (MCI) is a precursor of AD in many instances. MCI may be diagnosed when there is a change in cognition, but insufficient impairment for the diagnosis of dementia. Features of MCI are evidence of impairment in one or more cognitive domains and preservation of independence in functional abilities. In some patients, MCI may be a prodementia phase of AD. Patients with MCI may undergo ancillary testing (eg, neuroimaging, laboratory studies, neuropsychological assessment) to rule out vascular, traumatic, and medical causes of cognitive decline and to evaluate genetic factors.

Biomarker evidence has been integrated into the diagnostic criteria for probable and possible AD for use in research settings. Other diagnostic tests for AD include cerebrospinal fluid levels of tau protein or APP, as well as positron emission tomography amyloid imaging.

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests (LDTs) must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). Lab tests listed in Tables 1 and 3 are available under the auspices of CLIA. Laboratories that offer LDTs must be licensed by CLIA for high-complexity testing. To date, the U.S. FDA has chosen not to require any regulatory review of this test.

Centers for Medicare and Medicaid Services (CMS)

There is no national coverage determination (NCD). In the absence of an NCD, coverage decisions are left to the discretion of local Medicare carriers.

Rationale/Source

Evidence reviews assess whether a medical test is clinically useful. A useful test provides information to make a clinical management decision that improves the net health outcome. That is, the balance benefits and harms is better when the test is used to manage the condition than when another test or no test is used to manage the condition.

The first step in assessing a medical test is to formulate the clinical context and purpose of the test. The test must be technically reliable, clinically valid, and clinically useful for that purpose. Evidence reviews assess the evidence on whether a test is clinically valid and clinically useful. Technical reliability is outside the scope of these reviews, and credible information on technical reliability is available from other sources.

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Alzheimer's Disease

Policy # 00204

Original Effective Date: 05/17/2006

Current Effective Date: 11/21/2018

GENETIC TESTING FOR LATE-ONSET ALZHEIMER DISEASE

Clinical Context and Test Purpose

The purpose of genetic testing in patients who are asymptomatic and at risk for developing late-onset AD is potentially to inform management decisions such as early treatment or behavioral changes. Asymptomatic patients at risk of late-onset AD are not generally treated with medical therapy but may choose to make behavioral changes associated with reduced risk of AD.

The question addressed in this evidence review is: Does genetic testing improve health outcomes in individuals who are asymptomatic and at risk for developing late-onset AD?

The following PICOTS were used to select literature to inform this review.

Patients

The relevant population of interest is adults who are asymptomatic and at risk for developing late-onset AD due to family history of AD or dementia.

Interventions

The test being considered is genetic testing. It can be performed on a number of candidate genes, individually or collectively. Lists of genes associated with AD and testing laboratories in the United States are provided on the Genetic Testing Registry website of the National Center for Biotechnology Information. Table 1 lists examples of commercially available genetic panels for AD.

Table 1. Examples of Commercially Available Genetic Panels for Late-Onset Alzheimer Disease

Laboratory	Panel Name	No. of Genes		Testing Methods
		Tested		
Fulgent Genetics	Parkinson-Alzheimer-Dementia NGS Panel	37		NGS
Knight Diagnostic Laboratories	Dementia	21		Sequence analysis of the entire coding region
PreventionGenetics	Dementia Sequencing Panel	13		Deletion/duplication analysis; sequence analysis of entire coding region; targeted variant analysis

NGS: next-generation sequencing.

Comparators

The following practice is currently being used: standard clinical management without genetic testing.

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Alzheimer's Disease

Policy # 00204
Original Effective Date: 05/17/2006
Current Effective Date: 11/21/2018

Outcomes

The general outcomes of interest are change in disease status, health status measures, and quality of life. Specific outcomes in each of these categories are listed in Table 2.

The potential beneficial outcomes of primary interest would be change in disease status if changes in management or behavior in asymptomatic patients at risk of late-onset AD are initiated that prevent or slow progression of cognitive decline. Improvement in health status measures is also important.

Potential harmful outcomes are those resulting from a true- or false-positive test result. Patients might suffer from psychological harm or anxiety after receiving positive test results.

Table 2. Outcomes of Interest for Individuals With Symptomatic Late-Onset Alzheimer Disease

Outcomes	Details
Change in disease status	Incidence or time to Alzheimer disease onset; changes in cognitive test scores
Health status measures	Activities of daily living or functional scales such as the 36-Item Short-Form Health Survey, Alzheimer Disease Cooperative Study Activities of Daily Living scale, or Disability Assessment for Dementia
Quality of life	EuroQoL EQ-5D; measures of anxiety or depression

Timing

Trials of genetic testing in this population have been sparse and generally included short-term outcomes of distress and anxiety measured within a year. Trials of prevention strategies in AD typically span many years to a decade to detect differences in conversion to AD in asymptomatic, at-risk individuals.

Setting

Asymptomatic patients are likely to be managed in primary care. Genetic testing for variants associated with late-onset AD is complex. Referral for genetic counseling is important for the explanation of genetic disease, heritability, genetic risk, test performance, and possible outcomes.

Simplifying Test Terms

There are 3 core characteristics for assessing a medical test. Whether imaging, laboratory, or other, all medical tests must be:

- Technically reliable
- Clinically valid
- Clinically useful.

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Alzheimer's Disease

Policy # 00204

Original Effective Date: 05/17/2006

Current Effective Date: 11/21/2018

Because different specialties may use different terms for the same concept, we are highlighting the core characteristics. The core characteristics also apply to different uses of tests, such as diagnosis, prognosis, and monitoring treatment.

Diagnostic tests detect presence or absence of a condition. Surveillance and treatment monitoring are essentially diagnostic tests over a time frame. Surveillance to see whether a condition develops or progresses is a type of detection. Treatment monitoring is also a type of detection because the purpose is to see if treatment is associated with the disappearance, regression, or progression of the condition.

Prognostic tests predict the risk of developing a condition in the future. Tests to predict response to therapy are also prognostic. Response to therapy is a type of condition and can be either a beneficial response or adverse response. The term predictive test is often used to refer to response to therapy. To simplify terms, we use prognostic to refer both to predicting a future condition or to predicting a response to therapy.

Technically Reliable

Assessment of technical reliability focuses on specific tests and operators and requires review of unpublished and often proprietary information. Review of specific tests, operators, and unpublished data are outside the scope of this evidence review, and alternative sources exist. This evidence review focuses on the clinical validity and clinical utility.

Clinically Valid

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

Many studies have examined the association between the apolipoprotein $\epsilon 4$ allele (*APOE*E4*) and AD. The Rotterdam and Framingham studies are examples of large observational studies demonstrating the association. The Rotterdam Study was a prospective cohort study in the city of Rotterdam, the Netherlands, with main objectives of investigating risk factors of cardiovascular, neurologic, ophthalmologic, and endocrine diseases in the elderly. In a sample of 6852 participants, carriers of a single $\epsilon 4$ allele had a relative risk of developing AD approximately double that of $\epsilon 3/\epsilon 3$ carriers. Carriers of the two $\epsilon 4$ alleles had a relative risk of developing dementia approximately 8 times that of $\epsilon 3/\epsilon 3$ carriers. The Framingham Heart Study was a longitudinal cohort study initiated in 1948 in Framingham, Massachusetts, to identify common risk factors for cardiovascular disease. In 1030 participants, the relative risk for developing AD was 3.7 (95% confidence interval [CI], 1.9 to 7.5) for carriers of a single $\epsilon 4$ allele and 30.1 (95% CI, 10.7 to 84.4) for carriers with two $\epsilon 4$ alleles compared to those without an $\epsilon 4$ allele. The association between the *APOE*E4* allele and AD is significant; however, *APOE* genotyping does not have high specificity or sensitivity and is of little value in the predictive testing of asymptomatic individuals.

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Alzheimer's Disease

Policy # 00204

Original Effective Date: 05/17/2006

Current Effective Date: 11/21/2018

Associations between late-onset AD and more than 20 non-*APOE* genes have been suggested. Examples of large studies and meta-analyses on these non-*APOE* genes are discussed below.

Naj et al (2014) published a genome-wide association study (GWAS) of multiple genetic loci in late-onset AD. Genetic data from 9162 white participants with AD, from the Alzheimer Disease Genetics Consortium, were assessed for variants at 10 loci significantly associated with risk of late-onset AD. The analysis confirmed the association between *APOE* and early-onset and found significant associations for the *CR1*, *BIN1*, and *PICALM* genes. *APOE* contributed 3.7% of the variation in age of onset, and the other 9 loci combined contributed 2.2% of the variation. Each additional copy of the *APOE*E4* allele reduced the age of onset by 2.45 years.

Lambert et al (2013) published a large meta-analysis of GWAS of susceptibility loci for late-onset AD in 17,008 AD cases and 37,154 controls of European ancestry. Nineteen loci had genome-wide significance in addition to the *APOE* locus. The researchers confirmed several genes already reported to be associated with AD (*ABCA7*, *BIN1*, *CD33*, *CLU*, *CR1*, *CD2AP*, *EPHA1*, *MS4A6A-MS4A4E*, *PICALM*). New loci located included *HLA-DRB5-HLA-DRB1*, *PTK2B*, *SORL1*, and *SLC24A4-RIN3*.

Jonsson et al (2013) evaluated 3550 subjects with AD and found a genome-wide association for only 1 marker, the T allele of rs75932628 (excluding the *APOE* locus and the *APP11* A673T variant). The frequency of rs75932628 (triggering receptor expressed on myeloid cells 2 [*TREM2*]) was then tested in a general population of 110,050 Icelanders of all ages and found to confer a risk of developing AD of 0.63% (odds ratio [OR], 2.26; 95% CI, 1.71 to 2.98; $p=1.13 \times 10^{-8}$). In the control population of 8888 patients 85 years of age or older without a diagnosis of AD, the *TREM2* frequency was 0.46% (OR=2.92; 95% CI, 2.09 to 4.09; $p=3.42 \times 10^{-10}$). In 1236 cognitively intact controls age 85 or older, the frequency of *TREM2* decreased to 0.31% (OR=4.66; 95% CI, 2.38 to 9.14; $p=7.39 \times 10^{-6}$). The decrease in *TREM2* frequency in cognitively intact elderly patients supports findings associating *TREM2* with increasing risk of AD. Guerriero et al (2013) also found a strong association between the *TREM2* R47H variant and AD ($p=0.001$). Using 3 imputed datasets of GWAS, meta-analysis found a significant association between the variant and AD ($p=0.002$). The authors further reported direct genotyping of R47H in 1994 AD patients and 4062 controls, which detected a highly significant association between the variant and AD (OR=5.05; 95% CI, 2.77 to 9.16; $p=9.0 \times 10^{-9}$).

Clinically Useful

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy, or avoid unnecessary testing.

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Alzheimer's Disease

Policy # 00204

Original Effective Date: 05/17/2006

Current Effective Date: 11/21/2018

Direct Evidence

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from randomized controlled trials.

There are no randomized controlled trials comparing outcomes of asymptomatic adults at risk for developing late-onset AD managed with and without genetic testing for AD.

Chain of Evidence

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

The Risk Evaluation and Education for Alzheimer's Disease (REVEAL) study as reported by Chao et al (2008) was designed to examine the consequences of AD risk assessment by *APOE* genotyping. Of 289 eligible participants, 162 were randomized (mean age, 52.8 years; 73% female) to risk assessment based on *APOE* testing plus family history (n=111) or family history alone (n=51). During a 1-year follow-up, those undergoing *APOE* testing with a high-risk genotype were more likely than low-risk or untested individuals to take more vitamins (40% vs 24% and 30%), change diet (20% vs 11% and 7%), or change exercise behaviors (8% vs 4% and 5%), all respectively. There is insufficient evidence to conclude that these short-term behavioral changes would alter clinical outcomes. Green et al (2009) examined anxiety, depression, and test-related distress at 6 weeks, 6 months, and 1 year in the 162 participants randomized in REVEAL. However, there were no significant differences between the group that received the results of *APOE* testing and the group that did not in changes in anxiety or depression overall or the subgroup of participants with the *APOE***E4* allele. However, the $\epsilon 4$ negative participants had significantly lower test-related distress than $\epsilon 4$ positive participants ($p=0.01$).

Christensen et al (2016) examined disclosing associations between *APOE* genotype and AD risk alone vs AD and coronary artery disease (CAD) risk in an equivalence trial from the REVEAL group. Two hundred ninety participants were randomized to AD risk disclosure alone or AD plus CAD risk disclosure. The 257 participants who received their genetic information were included in analyses. Mean anxiety, depression, and test-related distress scores were below cutoffs for mood disorders at all time points in both disclosure groups and were similar to baseline levels. At the 12-month follow-up, both anxiety (measured by the Beck Anxiety Index) and depression (measured by the Center for Epidemiologic Studies Depression Scale) fell within the equivalence margin indicating no difference between disclosure groups. Among participants with an $\epsilon 4$ allele, distress (measured by Impact of Event Scale) was lower at 12 months in AD plus CAD group than in the AD-only group (difference, -4.8; 95% CI, -8.6 to -1.0; $p=0.031$). AD plus CAD participants also reported more health behavior changes than AD-alone participants, regardless of *APOE* genotype.

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Alzheimer's Disease

Policy # 00204

Original Effective Date: 05/17/2006

Current Effective Date: 11/21/2018

There is a lack of interventions that can delay or mitigate late-onset AD. There is no evidence that early intervention for asymptomatic disease-associated variant carriers can delay or mitigate future disease. There are many actions patients can take following knowledge of a disease-associated variant. Changes in lifestyle factors (eg, diet, exercise) and/or incorporation of "brain training" exercises can be made, but there is no evidence that these interventions impact clinical disease.

Section Summary: Genetic Testing for Late-Onset Alzheimer Disease

The *APOE*E4* allele is strongly associated with the incidence of and age at onset of AD; many other genes have shown statistical associations with AD incidence and onset, thus demonstrating some degree of clinical validity. However, the clinical sensitivity and specificity of the *APOE*E4* allele is poor, and there is a lack of evidence on the clinical sensitivity and specificity of other genes.

Literature searches did not identify any studies that address how the use of the *APOE* or other AD-associated genetic variants might be incorporated into clinical practice. It is also unclear how changes in the management of asymptomatic patients with these genes would improve outcomes. The REVEAL studies found short-term changes in behaviors following disclosure of *APOE* genetic testing results in high-risk adults with little increase in anxiety or depression overall, although with a possible increase in distress among $\epsilon 4$ allele carriers. It is unclear whether these changes in behaviors would improve clinical outcomes or whether there are long-term effects on psychological outcomes among $\epsilon 4$ carriers. Therefore, clinical utility has not been demonstrated for these tests.

GENETIC TESTING FOR EARLY-ONSET AD WITH AND WITHOUT A KNOWN FAMILIAL VARIANT

Clinical Context and Test Purpose

The purpose of genetic testing in patients who are asymptomatic and at risk for developing early-onset AD is to inform management decisions such as initiation of AD therapy and to inform reproductive decision making. Asymptomatic patients at risk for early-onset AD are not generally treated with medical therapy.

The question addressed in this evidence review is: Does genetic testing improve health outcomes in individuals who are asymptomatic, at risk for developing early-onset AD, and have a known or unknown familial variant?

The following PICOTS were used to select literature to inform this review.

Patients

The relevant population of interest is adults who are asymptomatic and at risk for developing early-onset AD due to family history of early-onset AD, specifically those with autosomal dominant AD.

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Alzheimer's Disease

Policy # 00204

Original Effective Date: 05/17/2006

Current Effective Date: 11/21/2018

Interventions

Adults with a family history of early-onset AD caused by a known pathogenic *APP*, *PSEN1*, or *PSEN2* variant would undergo targeted testing for the specific familial variant. In adults with a family history consistent with autosomal dominant AD but for whom the familial variant is unknown, genetic testing can be performed on the 3 genes (*APP*, *PSEN1*, *PSEN2*) individually or collectively. Multiple variants in these genes can cause early-onset AD, so sequencing the entire coding regions is necessary to comprehensively assess risk when the familial variant is unknown. Table 3 provides examples of commercially available genetic panels that include the early-onset, autosomal dominant variants.

Table 3. Examples of Commercially Available Genetic Panels for Early-Onset Alzheimer Disease

Laboratory	Panel Name	No. of Genes Tested	Testing Method
PreventionGenetics	Alzheimer Disease, Familial, Sequencing Panel	3	CGH, NGS, bidirectional Sanger sequence analysis
Athena Diagnostics	ADmark® Early Onset Alzheimer's Evaluation	3	Bidirectional Sanger sequence analysis
Fulgent Genetics	Early Onset Familial Alzheimer Disease NGS Panel	3	Deletion/duplication analysis; sequence analysis of entire coding region
PreventionGenetics	Alzheimer's Disease, Familial via the APP Gene, Exons 16 and 17; Familial via the PSEN1 Gene; Familial via the PSEN2 Gene	1 each test	Deletion/duplication analysis; sequence analysis of entire coding region; targeted variant analysis

CGH: comparative genomic hybridization; NGS: next-generation sequencing.

Comparators

The following practice is currently being used: targeted familial variant testing for those with a known familial variant and genetic testing for those without a known familial variant.

Outcomes

The general outcomes of interest are change in disease status, health status measures, quality of life, and changes in reproductive decision making.

The potential beneficial outcome of primary interest would be change in reproductive decision making. Changes in management in asymptomatic patients at risk of AD might be initiated with the intent to prevent or slow progression of cognitive decline leading to changes in disease status. Improvement in health status measures is also important.

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Alzheimer's Disease

Policy # 00204

Original Effective Date: 05/17/2006

Current Effective Date: 11/21/2018

Potential harmful outcomes are those resulting from a true- or a false-positive test result. Patients might suffer from psychological harm or anxiety after receiving positive test results.

Timing

Outcomes of reproductive decision making are relevant during child-bearing years for asymptomatic adults at risk.

Setting

Asymptomatic patients are likely to be managed in primary care. Reproductive decision making is a complex psychological process. Referral for genetic counseling is important for the explanation of genetic disease, heritability, genetic risk, test performance, and possible outcomes. The American College of Medical Genetics and Genomics and the National Society of Genetic Counselors guidelines have recommended that genetic testing for early-onset, autosomal dominant AD should only occur in the context of genetic counseling with support by someone expert in the area. In asymptomatic patients, a testing protocol based on the 1994 International Huntington Association and World Federation of Neurology Research Group on Huntington's Chorea guidelines has also been recommended.

Technically Reliable

Assessment of technical reliability focuses on specific tests and operators and requires review of unpublished and often proprietary information. Review of specific tests, operators, and unpublished data are outside the scope of this evidence review, and alternative sources exist. This evidence review focuses on the clinical validity and clinical utility.

Clinically Valid

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

In the scenario of targeted testing of individuals with a known familial pathogenic variant, due to nearly complete penetrance of pathogenic variants, an identified carrier will almost certainly develop the disease unless dying at an age preceding disease onset. Therefore, the clinical validity is nearly certain.

In the scenario of genetic testing of individuals with a family history consistent with autosomal dominant early-onset AD but in whom a pathogenic variant has not been found, the testing yield is less certain. Genetic testing for presenilin 1 (*PSEN1*) is estimated to detect disease-causing variants in 30% to 60% of individuals with familial early-onset AD, although estimates vary. A number of variants scattered throughout the *PSEN1* gene have been reported, requiring sequencing of the entire gene when the first affected member of a family with an autosomal dominant pattern of AD inheritance is tested. Variants in amyloid-beta precursor protein (*APP*) and presenilin 2 (*PSEN2*) genes account for another 10% to 20% of cases.

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Alzheimer's Disease

Policy # 00204

Original Effective Date: 05/17/2006

Current Effective Date: 11/21/2018

The Human Genome Variation Society maintains a catalog of identified pathogenic variants called the Alzheimer Disease & Frontotemporal Dementia Mutation Database. A pathogenic association (clinical validity) between variants and disease has been demonstrated for identified variants through the presence in related probands with nearly complete penetrance. Most of the *PSEN1*, *PSEN2*, and *APP* variants reported in the database (>200) are identified as pathogenic—over half by multiple studies.

Clinical expressivity is variable, ie, the presence of *PSEN1*, *PSEN2*, or *APP* variants is not useful in predicting the age of onset (although the age of onset is usually similar in affected family members), severity, type of symptoms, or rate of progression in asymptomatic individuals.

Clinically Useful

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy, or avoid unnecessary testing.

Direct Evidence

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from randomized controlled trials.

There are no randomized controlled trials comparing outcomes of asymptomatic adults at risk for developing early-onset AD managed with and without genetic testing for AD.

Chain of Evidence

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

The potential clinical utility of testing is early identification of asymptomatic patients who are at risk for developing early-onset AD. Genetic testing will in most cases lead to better risk stratification, distinguishing patients who will develop the disease from those who will not. If the early identification of patients at risk leads to interventions to delay or mitigate clinical disease, then clinical utility would be established. Identification of asymptomatic, young adult carriers could impact reproductive planning. And clinical utility may be demonstrated if testing leads to informed reproductive planning that improves outcomes. Alternatively, clinical utility could be demonstrated if knowledge of variant status leads to beneficial changes in psychological outcomes.

A systematic review, reported by Rahman et al (2012), which assessed of the psychological and behavioral impact of genetic testing for AD, found few studies on the impact of testing for early-onset familial AD. The

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Alzheimer's Disease

Policy # 00204

Original Effective Date: 05/17/2006

Current Effective Date: 11/21/2018

existing studies generally have small sample sizes and retrospective designs, and the research was conducted in different countries, which may limit the generalizability of the findings.

There is no evidence that early intervention for asymptomatic pathogenic variant carriers can delay or mitigate future disease. There are many actions patients may take following knowledge of a pathogenic variant: changes in lifestyle factors (eg, diet, exercise) and incorporation of "brain training" exercises; but there is no evidence that these interventions impact clinical disease.

When a known pathogenic variant is identified in a prospective parent, with reasonable certainty, the disease will develop, and there is a 50% risk of an affected offspring. For purposes of informing family planning, when a pathogenic variant is detected in a prospective parent, the prospective parent can choose to refrain from having children or choose medically assisted reproduction during which preimplantation testing would allow a choice to avoid an affecting offspring. Identification of a pathogenic variant by genetic testing is more accurate than the alternative of obtaining a family history alone. Therefore, testing in the reproductive setting can improve health outcomes.

Section Summary: Genetic Testing for Early-Onset AD

The clinical validity for autosomal dominant, early-onset AD will be nearly certain when a pathogenic variant has previously been identified in a family pedigree or the variant database.

For those from families with early-onset, familial AD, when a pathogenic familial variant is known or when the family pedigree is consistent with autosomal dominant AD but the affected family members have not been tested to determine the familial variant, testing a prospective parent when performed in conjunction with genetic counseling provides more accurate information to guide reproductive planning than family history alone. Therefore, the clinical utility for the purposes of reproductive decision making has been demonstrated for these tests. There are currently no known preventive measures or treatments that can mitigate the effect of AD. It is not clear how a change in the management of asymptomatic patients with these genes would improve outcomes. Outside the reproductive setting when used for prognosis or prediction, there is insufficient evidence to draw conclusions on the benefits of genetic testing for pathogenic variants.

SUMMARY OF EVIDENCE

For individuals who are asymptomatic and at risk for developing late-onset AD who receive genetic testing, the evidence includes studies on gene associations, test accuracy, and effects on health outcomes. Relevant outcomes are test accuracy and validity, change in disease status, health status measures, and quality of life. Many genes, including *APOE*, *CR1*, *BIN1*, *PICALM*, and *TREM2*, are associated with late-onset AD. However, the sensitivity and specificity of genetic testing for indicating which individuals will progress to AD is low, and numerous other factors can affect progression. Overall, genetic testing has not

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Alzheimer's Disease

Policy # 00204

Original Effective Date: 05/17/2006

Current Effective Date: 11/21/2018

been shown to add value to the diagnosis of AD made clinically. The current lack of effective methods to prevent the onset of AD or to target AD treatments based on genetic characteristics limits the clinical benefit for genetic testing. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who are asymptomatic, at risk for developing early-onset, autosomal dominant AD, and have a known familial variant who receive targeted genetic testing, the evidence includes studies on gene associations and test accuracy. Relevant outcomes are test accuracy and validity, change in disease status, change in reproductive decision making, health status measures, and quality of life. Variants in the *PSEN1* and *PSEN2* and *APP* genes are known to cause early-onset AD in an autosomal dominant pattern with almost complete penetrance. The clinical validity for autosomal dominant early-onset AD will be nearly certain when a familial pathogenic variant has previously been identified. Outside the reproductive setting when used for prognosis or prediction, there is insufficient evidence to draw conclusions on the benefits of genetic testing for pathogenic variants. Testing a prospective parent, when performed in conjunction with genetic counseling, provides more accurate information to guide reproductive planning than family history alone. Therefore, clinical utility for the purposes of reproductive decision making has been demonstrated for these tests. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who are asymptomatic, at risk for developing early-onset, autosomal dominant AD, and have no known familial variant who receive genetic testing, the evidence includes studies on gene associations and test accuracy. Relevant outcomes are test accuracy and validity, change in disease status, change in reproductive decision making, health status measures, and quality of life. Variants in the *PSEN1*, *PSEN2*, and *APP* genes are known to cause early-onset AD in an autosomal dominant pattern with almost complete penetrance. The clinical validity for autosomal dominant early-onset AD will be reasonably certain when a variant found in the database of pathogenic *PSEN1*, *PSEN2*, and *APP* variants are identified. Outside the reproductive setting when used for prognosis or prediction, there is insufficient evidence to draw conclusions on the benefits of genetic testing for pathogenic variants. Testing a prospective parent, when performed in conjunction with genetic counseling, provides more accurate information to guide reproductive planning than family history alone. Therefore, clinical utility for the purposes of reproductive decision making has been demonstrated for these tests. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

References

1. Blue Cross and Blue Shield Association, Medical Policy Reference Manual, "Genetic Testing for Alzheimer Disease", 2.04.13, 4:2018.
2. Bird TD. Genetic aspects of Alzheimer disease. *Genet Med.* Apr 2008;10(4):231-239. PMID 18414205

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Alzheimer's Disease

Policy # 00204

Original Effective Date: 05/17/2006

Current Effective Date: 11/21/2018

3. Goldman JS, Hahn SE, Catania JW, et al. Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. *Genet Med*. Jun 2011;13(6):597-605. PMID 21577118
4. Caselli RJ, Dueck AC, Locke DE, et al. Cerebrovascular risk factors and preclinical memory decline in healthy APOE epsilon4 homozygotes. *Neurology*. Mar 22 2011;76(12):1078-1084. PMID 21325652
5. Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. *N Engl J Med*. Jan 10 2013;368(2):107-116. PMID 23150908
6. Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in Alzheimer's disease. *N Engl J Med*. Jan 10 2013;368(2):117-127. PMID 23150934
7. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*. May 2011;7(3):263-269. PMID 21514250
8. Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. *Alzheimers Dement*. Jan 2012;8(1):1-13. PMID 22265587
9. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*. May 2011;7(3):270-279. PMID 21514249
10. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Genetic Testing for Alzheimer's Disease: APOE Epsilon 4 Allele. TEC Assessments. 1999;Volume 14:Tab 7.
11. National Center for Biotechnology Information. Genetic Testing Registry. <https://www.ncbi.nlm.nih.gov/gtr/>. Accessed March 16, 2017.
12. Slooter AJ, Cruts M, Hofman A, et al. The impact of APOE on myocardial infarction, stroke, and dementia: the Rotterdam Study. *Neurology*. Apr 13 2004;62(7):1196-1198. PMID 15079025
13. Myers RH, Schaefer EJ, Wilson PW, et al. Apolipoprotein E epsilon4 association with dementia in a population-based study: The Framingham study. *Neurology*. Mar 1996;46(3):673-677. PMID 8618665
14. Bird TD. Alzheimer Disease Overview. *GeneReviews*. 2015. PMID 20301340
15. Naj AC, Jun G, Reitz C, et al. Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study. *JAMA Neurol*. Nov 2014;71(11):1394-1404. PMID 25199842
16. Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nat Genet*. Dec 2013;45(12):1452-1458. PMID 24162737
17. Chao S, Roberts JS, Marteau TM, et al. Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study. *Alzheimer Dis Assoc Disord*. Jan-Mar 2008;22(1):94-97. PMID 18317253
18. Green RC, Roberts JS, Cupples LA, et al. Disclosure of APOE genotype for risk of Alzheimer's disease. *N Engl J Med*. Jul 16 2009;361(3):245-254. PMID 19605829
19. Christensen KD, Roberts JS, Whitehouse PJ, et al. Disclosing pleiotropic effects during genetic risk assessment for Alzheimer disease: a randomized trial. *Ann Intern Med*. Feb 02 2016;164(3):155-163. PMID 26810768
20. International Huntington Association and the World Federation of Neurology Research Group on Huntington's Chorea. Guidelines for the molecular genetics predictive test in Huntington's disease. *J Med Genet*. Jul 1994;31(7):555-559. PMID 7966192
21. Kowalska A, Wender M, Florczak J, et al. Molecular genetics of Alzheimer's disease: presenilin 1 gene analysis in a cohort of patients from the Poznan region. *J Appl Genet*. 2003;44(2):231-234. PMID 12817569
22. Janssen JC, Beck JA, Campbell TA, et al. Early onset familial Alzheimer's disease: Mutation frequency in 31 families. *Neurology*. Jan 28 2003;60(2):235-239. PMID 12552037
23. Alzheimer Disease & Frontotemporal Dementia Mutation Database. <http://www.molgen.vib-ua.be/ADMutations/>. Accessed March 16, 2017.
24. Rahman B, Meiser B, Sachdev P, et al. To know or not to know: An update of the literature on the psychological and behavioral impact of genetic testing for Alzheimer Disease risk. *Genet Test Mol Biomarkers*. 2012;16(8):1-8. PMID
25. American College of Medical Genetics and Genomics. Choosing Wisely. 2015; <http://www.choosingwisely.org/societies/american-college-of-medical-genetics-and-genomics/>. Accessed October 6, 2015.

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Alzheimer's Disease

Policy # 00204
Original Effective Date: 05/17/2006
Current Effective Date: 11/21/2018

26. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. May 08 2001;56(9):1143-1153. PMID 11342678
27. Hort J, O'Brien JT, Gainotti G, et al. EFNS guidelines for the diagnosis and management of Alzheimer's disease. *Eur J Neurol*. 2010;17(10):1236-1248.
28. Gauthier S, Patterson C, Chertkow H, et al. Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4). *Can Geriatr J*. Dec 2012;15(4):120-126. PMID 23259025
29. 3rd Canadian Consensus Conference on Diagnosis and Treatment of Dementia (approved July 2007). New Consensus Guidelines on Management of Dementia. 2008; http://www.cccdt.ca/pdfs/Final_Recommendations_CCCDTD_2007.pdf. Accessed August 6, 2015.

Policy History

Original Effective Date: 05/17/2006
Current Effective Date: 11/21/2018

05/03/2006	Medical Director review
06/21/2006	Medical Policy Committee approval
11/05/2008	Medical Director review
11/18/2008	Medical Policy Committee approval. No change to coverage eligibility.
11/04/2010	Medical Policy Committee review
11/16/2010	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
11/03/2011	Medical Policy Committee review
11/16/2011	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
11/01/2012	Medical Policy Committee review
11/28/2012	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
11/07/2013	Medical Policy Committee review
11/20/2013	Medical Policy Implementation Committee approval. TREM2 added to investigational policy statement.
11/06/2014	Medical Policy Committee review
11/21/2014	Medical Policy Implementation Committee approval. No change to coverage.
01/01/2015	Coding Update
08/03/2015	Coding update: ICD10 Diagnosis code section added; ICD9 Procedure code section removed.
10/29/2015	Medical Policy Committee review
11/16/2015	Medical Policy Implementation Committee approval. No change to coverage.
11/03/2016	Medical Policy Committee review
11/16/2016	Medical Policy Implementation Committee approval. No change to coverage.
01/01/2017	Coding update: Removing ICD-9 Diagnosis Codes
11/02/2017	Medical Policy Committee review
11/15/2017	Medical Policy Implementation Committee approval. Policy and evidence reviewed separately for late-onset and early-onset Alzheimer disease. Policy statement changed to eligible for coverage for autosomal dominant early-onset AD for reproductive decision making.
11/08/2018	Medical Policy Committee review
11/21/2018	Medical Policy Implementation Committee approval. Added "early onset" to coverage statement.

Next Scheduled Review Date: 11/2019

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Alzheimer's Disease

Policy # 00204
 Original Effective Date: 05/17/2006
 Current Effective Date: 11/21/2018

Coding

The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT)[®]†, copyright 2017 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

Code Type	Code
CPT	81401, 81405, 81406
HCPCS	S3852
ICD-10 Diagnosis	All related diagnoses

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. FDA and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
 - 1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
 - 2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
 - 3. Reference to federal regulations.

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Alzheimer's Disease

Policy # 00204

Original Effective Date: 05/17/2006

Current Effective Date: 11/21/2018

**Medically Necessary (or "Medical Necessity") - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. In accordance with nationally accepted standards of medical practice;
- B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
- C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, "nationally accepted standards of medical practice" means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.